Christopher Gibson, Chief Executive Officer at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 120,000 shares at $4.71 ($471K) on 2025-09-10, disclosed to the SEC on 2025-09-12.
Scheduled sale ($471k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 20,000 | $0 | 0.0% |
| 2 | $4.71 | 100,000 | $471K | 100.0% |
| Total | $3.92 avg | 120,000 | $471K | 100% |
| Filing → |
| RXRX | SELL | 2026-05-08 | $135K | — | Filing → |
| RXRX | SELL | 2026-04-24 | $144K | — | Filing → |
| RXRX | SELL | 2026-04-08 | $124K | — | Filing → |